Variables

Univariate

Multivariate

Hazard Ratio (95% CI) p-value

Hazard Ratio (95% CI) p-value

Age ≥ 65 y (vs. <65 y)

3.162 (2.152 < 4.644)

<0.001

2.611 (1.739 < 3.920)

<0.001

Male gender (Y/N)

1.230 (0.880 < 1.718)

0.226

MPO-ANCA (vs. PR3-ANCA)

0.899 (0.517 < 1.562)

0.705

General manifestation (Y/N)

1.002 (0.701 < 1.430)

0.993

ENT involvement (Y/N)

0.860 (0.352 < 2.1)

0.740

Cardiovascular involvement (Y/N)

1.187 (0.839 < 1.680)

0.334

Abdominal involvement (Y/N)

1.536 (1.086 < 2.171)

0.015

0.935 (0.619 < 1.413)

0.751

Nervous system involvement (Y/N)

0.934 (0.546 < 1.598)

0.804

Pulmonary involvement (Y/N)

1.432 (1.024 < 2.004)

0.036

1.156 (0.718 < 1.860)

0.551

ILD (Y/N)

1.515 (1.07 < 2.145)

0.019

1.042 (0.622 < 1.747)

0.875

Alveolar hemorrhage (Y/N)

1.298 (0.829 < 2.031)

0.254

Kidney involvement (Y/N)

1.728 (1.026 < 2.912)

0.040

0.826 (0.453 < 1.503)

0.531

SCR ≥ 500 μmol/L (vs. <500 μmol/L)

1.935 (1.376 < 2.721)

<0.001

1.546 (1.075 < 2.224)

0.019

C3 ≤ 0.8 g/L (vs. >0.8 g/L)

2.554 (1.779 < 3.667)

<0.001

1.696 (1.148 < 2.507)

0.008

Hemoglobin ≤ 90 g/L (vs. >90 g/L)

1.998 (1.419 < 2.813)

<0.001

1.322 (0.893 < 1.959)

0.163

ALB < 30 g/L (vs. ≥30 g/L)

1.843 (1.316 < 2.580)

<0.001

1.438 (1.010 < 2.047)

0.044

BVAS ≥ 15 (vs. <15)

2.979 (2.114 < 4.197)

<0.001

1.943 (1.317 < 2.866)

0.001

Immunosuppressive treatment (Y/N)

0.757 (0.541 < 1.058)

0.103